Dr Alexis Lee Kleinman, DMD in Albany, NY - Medicare Oral Surgery Provider

Dr Alexis Lee Kleinman, DMD is a medicare enrolled "Dentist - Oral And Maxillofacial Surgery" provider in Albany, New York. She went to University Of Connecticut School Of Dental Medicine and graduated in 2008 and has 16 years of diverse experience with area of expertise as Oral Surgery. She is a member of the group practice Kaiser Foundation Health Plan Of The Northwest and her current practice location is 2 Executive Park Dr, Albany Oms Group, Albany, New York. You can reach out to her office (for appointments etc.) via phone at (518) 446-1001.

Dr Alexis Lee Kleinman is licensed to practice in Oregon (license number D10023) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1316217540.

Contact Information

	Dr Alexis Lee Kleinman, DMD
	2 Executive Park Dr, Albany Oms Group, Albany, NY 12203-3700
	(518) 446-1001
	Not Available

Healthcare Provider's Profile

Full Name	Dr Alexis Lee Kleinman
Gender	Female
Speciality	Oral Surgery
Experience	16 Years
Location	2 Executive Park Dr, Albany, New York
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Alexis Lee Kleinman attended and graduated from University Of Connecticut School Of Dental Medicine in 2008

NPI Data:

NPI Number: 1316217540
Provider Enumeration Date: 01/04/2012
Last Update Date: 07/29/2014

Medicare PECOS Information:

PECOS PAC ID: 2062632771
Enrollment ID: I20141001000844

Medical Identifiers

Medical identifiers for Dr Alexis Lee Kleinman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1316217540	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1223S0112X	Dentist - Oral And Maxillofacial Surgery	D10023 (Oregon)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Kaiser Foundation Health Plan Of The Northwest	5799688230	1482

News Archive

Common genetic defect in beta cells may underlie both known forms of diabetes

New research by Dr. Sylvie Lesage, scientist at Maisonneuve-Rosemont Hospital and associate research Professor at University of Montreal, just published in the prestigious international scientific journal Nature Genetics, has discovered that a common genetic defect in beta cells may underlie both known forms of diabetes.

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

LifeSensors, Inc., a biotechnology company specializing in protein expression technologies and ubiquitin pathway research tools, announced today their worldwide, exclusive license for high affinity ubiquitin traps. These new research tools, developed by Dr. Manuel S. Rodriguez of the proteomics unit of the CICbioGUNE in Spain, will be launched in October 2009.

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Alexis Lee Kleinman allows following entities to bill medicare on her behalf.

Entity Name	Kaiser Foundation Health Plan Of The Northwest
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799

News Archive

Common genetic defect in beta cells may underlie both known forms of diabetes

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Alexis Lee Kleinman is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Alexis Lee Kleinman, DMD 19075 Nw Tanasbourne Drive #300, Sunset Dental Office, Hillsboro, OR 97124-3700 Ph: (503) 531-1700	Dr Alexis Lee Kleinman, DMD 2 Executive Park Dr, Albany Oms Group, Albany, NY 12203-3700 Ph: (518) 446-1001

News Archive

Common genetic defect in beta cells may underlie both known forms of diabetes

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Dentist in Albany, NY

Thao Luong, Dentist Medicare: Not Enrolled in Medicare Practice Location: 1873 Western Ave Ste 200, Albany, NY 12203 Phone: 518-436-7815
Dr. Michael A Landau, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 1467 Western Ave, Albany, NY 12203 Phone: 518-438-4400
Usha Jonnalagadda, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 314 S Manning Blvd, Albany, NY 12208 Phone: 518-453-2273
Dr. Richard H Cipolaro, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 113 Holland Ave, Albany, NY 12208 Phone: 518-626-6572
Dr. Champaka Lakshmi, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 5 Pine West Plz, Washigtonavenue Extension, Albany, NY 12205 Phone: 518-456-7673
Sneha Reddy Godi, Dentist Medicare: Not Enrolled in Medicare Practice Location: 1873 Western Ave, Suite 200, Albany, NY 12203 Phone: 518-869-1044
Dr. Amrutha Chandra Mandava, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1662 Central Ave, Albany, NY 12205 Phone: 518-452-2121 Fax: 518-456-2865

Dr Alexis Lee Kleinman, DMD - Medicare Dentist in Albany, NY

Contact Information

Healthcare Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Common genetic defect in beta cells may underlie both known forms of diabetes

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Medicare Reassignments

Common genetic defect in beta cells may underlie both known forms of diabetes

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Common genetic defect in beta cells may underlie both known forms of diabetes

CICbioGUNE develops Tandem-repeated Ubiquitin Binding Entities for purifying ubiquitylated proteins

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Dentist in Albany, NY